UGE International

HUMACYTE (NASDAQ: HUMA) STOCK QUOTE

Last Trade: US$4.76 0.01 0.21
Volume: 503,776
5-Day Change: 4.39%
YTD Change: -34.34%

LATEST NEWS FROM HUMACYTE

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D., Chief Operating Officer, will deliver a corporate presentation in-person at the H.C. Wainwright Global Investment Conference taking place both virtually and in-person at the... Read More
Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data Conference call and live webcast at 8:00 a.m. ET today Humacyte, Inc. (Nasdaq: HUMA), a... Read More
First shipment of HAVs to six Ukrainian hospitals made today Product candidate to be used for civilian and military vascular trauma repair, the HAV’s lead investigational indication Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the launch of an initiative to provide Human Acellular Vessels... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2022, on Friday, May 13, 2022. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title: Humacyte First Quarter 2022 Financial... Read More
Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that its 2022 annual meeting of shareholders will be held virtually on Thursday, June 9, 2022, at 7:30 AM eastern time. The record date for those eligible to receive notice of and to vote at the annual meeting is Monday, April 18, 2022. About... Read More
Advancing late-stage clinical and preclinical programs of the Human Acellular Vessel™ (HAV™) and other engineered tissues across several indications Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results Conference call and live webcast at 8:00 am ET today Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and full year ended December 31, 2021, on Tuesday, March 29, 2022. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title: Humacyte Fourth... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March. Cowen’s 42nd Annual Health Care Conference (March 7-9, 2022) Format: Virtual... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a virtual fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 15, 2022, at 9... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that results from the first series of compassionate use cases of Humacyte’s Human Acellular Vessel TM (HAV) will be presented at the 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society (VESS) in Snowmass, Colo. at 7:56 a.m.... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the first preclinical results of the use of Humacyte’s Human Acellular Vessel™ (HAV) in coronary artery bypass grafting (CABG) will be presented at the Advanced Therapies Week conference in Miami, Fla. at 9:20 a.m. EST on January 28, 2022. The... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Surgical Key Opinion Leaders (KOLs) Alan P. Kypson, M.D., FACS; Luigi Pascarella, M.D., FACS; and Todd E. Rasmussen, M.D., FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, the KOLs will lend their expertise and... Read More
Vanderbilt University Medical Center patient received the HAV under the U.S. Food and Drug Administration’s (FDA) Expanded Access Program (EAP) in April 2019 After replacement, the patient resumed regular physical activity with no signs of infection of the HAV implant observed Published in Journal of Vascular Surgery: Cases, Innovations and Techniques HAV used in 20 EAP cases to date, for treatment of severe vascular disease... Read More
Patency and host cell remodeling of the HAV were observed in all study implants Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac bypass surgery application Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced positive results from a preclinical... Read More
Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials 83% secondary patency observed at 12 months post-implantation Data presented today in keynote presentation at 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS2021) Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage... Read More
Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the Credit Suisse 30th Annual Healthcare Conference taking place virtually, on Nov. 10, 2021, at 1 p.m. EST. The webcast will be available for replay for at least 30 days... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that leadership will present new data and additional information on its programs at several scientific events in November 2021. “Humacyte is creating off-the-shelf universally implantable bioengineered human tissues to potentially transform the... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that senior leadership will present at seven scientific and industry events in October 2021. “We’ve made remarkable progress with our human acellular vessel (HAV) and continue to advance the HAV through multiple late-stage clinical and preclinical... Read More
Patent estate also expanded by the issuance of 23 additional patents in international markets Humacyte now owns or licenses 119 patents covering its proprietary platform Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the issuance of three additional U.S. patents covering its proprietary... Read More
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that senior leadership will present at five scientific and medical events in September 2021. “We’re pioneering the first engineered off-the-shelf human acellular vessel (HAV) and are wholly committed to realizing the full potential of our HAV across... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS